Free Trial
LON:MVI

Marwyn Value Investors 9/30/2025 Earnings Report

Marwyn Value Investors logo
GBX 137 +1.00 (+0.74%)
As of 10:52 AM Eastern

Marwyn Value Investors EPS Results

Actual EPS
GBX 4.53
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Marwyn Value Investors Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Marwyn Value Investors Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Marwyn Value Investors Earnings Headlines

Microscopic Footage Shows Immune Cells Attacking Cancer
Early human trial data from one NASDAQ-listed biotech showed up to a 63.7% reduction in cancer burden using its TriKE platform, which is designed to keep Natural Killer cells active and targeted longer than standard approaches. The company's next-generation version shows potential for 10-40x greater potency and has already cleared an important FDA milestone. Watch the microscopic footage and see what the next catalyst could mean for investors.tc pixel
Marwyn Value Investors’ AGM Resolutions Passed
See More Marwyn Value Investors Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Marwyn Value Investors? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Marwyn Value Investors and other key companies, straight to your email.

About Marwyn Value Investors

Marwyn Value Investors (LON:MVI) Limited specializes in investments in growth capital, buyout, industry consolidation, and acquisition-led growth strategies in small and mid-cap businesses. The fund also invests in consolidation opportunities in industry sectors that are undergoing structural or regulatory change, and is sector agnostic. It follows the buy-and-build strategy. It invests in companies based in Europe with a focus on the United Kingdom and North America. The fund seeks to invest in companies with enterprise value of EUR150 million ($158.11 million) to EUR1500 million ($1581.1 million). It prefers to take an equity stake.

View Marwyn Value Investors Profile